Although immunotherapy has remarkable heterogeneity regarding its objective response rate and survival, we and others have tried to optimise patient benefit by using various parameters, such as clinicopathologic factors [6-9], laboratory (neutrophil-to-lymphocyte ratio [NLR] [10], platelet-to-lymphocyte ratio [10], lactate dehydrogenase [LDH] [6,11,12], serum C-reactive protein [CRP] [6,13], and tumour markers [14]), and body composition parameters [15]. Here, CRP is linked to neoplasm.